# Vera Therapeutics Atacicept IgAN BLA Reaches PDUFA Decision Date of July 7, 2026

> fda · REPORTED · 2026-07-07

Vera Therapeutics' atacicept, a first-in-class BAFF and APRIL dual-targeting fusion protein for IgA nephropathy, has a PDUFA target action date of July 7, 2026 under FDA Priority Review and Breakthrough Therapy Designation. Phase 3 ORIGIN 3 data showed a 46% reduction in proteinuria from baseline and 42% reduction versus placebo (p less than 0.0001), with accelerated approval sought via the Biologics License Application pathway.

- Company: Vera Therapeutics
- Sector: therapeutics
- Primary source: https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-us-fda-granted-priority-review

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.